CVRxCVRX
Market Cap: $197M
About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Employees: 200
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
3,472% more call options, than puts
Call options by funds: $893K | Put options by funds: $25K
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
3.92% less ownership
Funds ownership: 65.0% [Q1] → 61.08% (-3.92%) [Q2]
16% less funds holding
Funds holding: 87 [Q1] → 73 (-14) [Q2]
36% less capital invested
Capital invested by funds: $248M [Q1] → $158M (-$89.8M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Cantor Fitzgerald Ross Osborn 34% 1-year accuracy 20 / 58 met price target | 55%upside $14 | Overweight Initiated | 10 Sept 2024 |
Lake Street Frank Takkinen 47% 1-year accuracy 9 / 19 met price target | 33%upside $12 | Buy Reiterated | 26 Aug 2024 |
Piper Sandler Matt O'Brien 52% 1-year accuracy 22 / 42 met price target | 44%upside $13 | Overweight Maintained | 30 Jul 2024 |
Canaccord Genuity William Plovanic 41% 1-year accuracy 7 / 17 met price target | 66%upside $15 | Buy Maintained | 30 Jul 2024 |
Craig-Hallum Alexander Nowak 88% 1-year accuracy 7 / 8 met price target | 66%upside $15 | Buy Maintained | 11 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CVRX published over the past 30 days